A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Erlotinib; Sorafenib
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 02 Mar 2009 Planned end date changed from 1 Dec 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
- 02 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2008 New trial record.